CARGO Therapeutics
CARGO Therapeutics develops next-generation CAR T-cell therapies to combat cancer, with its lead program CRG-022 targeting CD22 in B-cell malignancies.
Company History
CARGO Therapeutics was founded in 2019 by experts from Stanford University along with a cancer advocate. The company focuses on immuno-oncology and CAR T-cell engineering. Headquartered at 835 Industrial Road, Suite 400, San Carlos, CA 94070, CARGO Therapeutics went public on November 10, 2023, and is listed on the NASDAQ Global Select Market under the symbol 'CRGX'.
Lead Program CRG-022
CRG-022, CARGO Therapeutics' lead program, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen found in a majority of B-cell malignancies. It is in a potentially pivotal Phase 2 clinical trial for patients with large B-cell lymphoma (LBCL) whose disease was unresponsive to CD19 CAR T-cell therapy. Future plans include evaluating CRG-022 in patients at earlier stages of disease, including LBCL and other hematologic malignancies. The ongoing multi-center Phase 2 trial, named FIRCE-1, has an Independent Data Monitoring Committee's recommendation for continuation.
Innovative CAR T-cell Therapies
CARGO Therapeutics develops next-generation CAR T-cell therapies focused on outsmarting cancer to deliver more cures for patients. The company uses proprietary cell engineering platform technologies to create multi-specific, multi-functional CAR T-cells. These technologies include the STASH platform for multiplex engineering of immune cell types, which allows for the production of homogeneous CAR T-cell populations, and a CD2 platform to enhance activation against tumors that do not express CD58.
Product Pipeline
Alongside CRG-022, CARGO Therapeutics is developing CRG-023, a tri-specific CAR T-cell product aimed at CD19, CD20, and CD22 antigens. CRG-023 integrates a CD2 costimulatory domain to counter resistance mechanisms such as antigen loss and lack of T-cell persistence. The company leverages technologies for the incorporation of multiple genetic inserts delivered by multiple vectors and employs an automated and closed platform for a commercially viable manufacturing process.
Clinical Trials and Access
CARGO Therapeutics' investigational therapies, including CRG-022, can currently only be accessed through participation in clinical trials. There is no expanded access program available at this time. The company actively reports quarterly and annual financial results, with the fiscal year ending on December 31st. The Independent Data Monitoring Committee recommended the continuation of the FIRCE-1 study for CRG-022.